Small Molecules for Treatment of Retinal Degenerative Diseases

Christopher Lindsey\textsuperscript{1,2}, Craig Beeson\textsuperscript{1,2}, Baerbel Rohrer\textsuperscript{1,2}, Yuri Peterson\textsuperscript{2}, Nathan Perron\textsuperscript{2}, Cecile Nasarre\textsuperscript{2}, Mausumi Bandyopadhyay\textsuperscript{2}, Richard Comer\textsuperscript{1}, Kimberly Casalvieri\textsuperscript{1}

\textsuperscript{1}MitoChem Therapeutics Inc., Charleston, SC, USA, \textsuperscript{2}Medical University of South Carolina, Charleston, SC, USA

Retinitis Pigmentosa (RP) is a family of progressive retinal degenerative diseases that affects small populations. The diseases are associated with many different genes hindering drug development – there are currently no treatments. We have hypothesized that metabolic stress is downstream to many of the gene mutations. Recently, a high throughput screen (HTS) was developed under conditions that mimic RP\textsuperscript{1}. Hits from this primary screen were then subjected to a second assay that measures mitochondrial flux capacity, addressing the oxidative stress component affiliated with this neurodegenerative process. Two of these hits, CB11 and CB12, come together to form a pharmacophore from which novel chemical entities were synthesized. From these efforts, a small panel of analogs were developed and tested as a means to optimize protection of mitochondria from metabolic stress. Achieving cellular protection via the cell’s “power house” offers a novel approach towards treating this disease and the potential for addressing other pathologies where mitochondria are part of the degenerative process.